Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | CD38 | P28907 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484206 | 1.00 | POLB (0.37) | POLBKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL4477532 | 0.95 | ATM (0.36) | KMT2AALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL4477525 | 0.95 | ATM (0.36) | KMT2AALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL4475604 | 0.95 | KMT2A (0.37) | KMT2AALDH1A1KDM4EMEN1LMNA | |
| SCHEMBL4475609 | 0.95 | KMT2A (0.37) | KMT2AALDH1A1KDM4EMEN1LMNA | |
| SCHEMBL4492162 | 0.94 | LMNA (0.37) | KMT2AALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL4492169 | 0.94 | LMNA (0.37) | KMT2AALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL4477274 | 0.93 | LMNA (0.40) | KMT2AALDH1A1KDM4EMEN1LMNA | |
| SCHEMBL4477265 | 0.93 | LMNA (0.40) | KMT2AALDH1A1KDM4EMEN1LMNA | |
| SCHEMBL4476774 | 0.93 | KDM4E (0.38) | KMT2AKDM4EMEN1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582651-B2 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-01 | — | — | US | disclosed |
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1535922-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | OPRD1, TRPV1, OPRM1 | POLB 3355/4885KMT2A 3881/4885ALDH1A1 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.